1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neuroimmunology Drugs Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Small Molecules
5.4 Recombinant Protein
5.5 Cytokines
5.6 Lymphocytes
5.7 Other Product Types
6 Global Neuroimmunology Drugs Market, By Indication
6.1 Introduction
6.2 Multiple Sclerosis
6.3 Alzheimer’s Disease
6.4 Parkinson’s Disease
6.5 Myasthenia Gravis
6.6 Guillain-Barre Syndrome
6.7 Neuromyelitis Optica Spectrum Disorder
6.8 Amyotrophic Lateral Sclerosis
6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
6.10 Other Indications
7 Global Neuroimmunology Drugs Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Biogen
9.2 Hoffmann-La Roche Ltd
9.3 T3D Therapeutics
9.4 Novartis AG
9.5 Celgene Corp
9.6 Merck KGaA
9.7 Johnson & Johnson
9.8 Eisai Co Ltd
9.9 Sanofi
9.10 Actelion Pharmaceuticals Ltd.
9.11 ImmunoBrain Checkpoint
9.12 Lundbeck
9.13 Eli Lilly
9.14 AstraZeneca
9.15 UCB SA
9.16 AB Science S.A.
9.17 AstronauTx
9.18 Genetech Inc
9.19 Inflammasome Therapeutics
9.20 TauRX Therapeutics Ltd
List of Tables
Table 1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 12 Global Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 30 North America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 84 South America Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
Table 91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
Table 93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
Table 95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
Table 96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
Table 97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
Table 98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
Table 100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
Table 102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson’s Disease (2021-2030) ($MN)
Table 103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
Table 104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
Table 105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
Table 106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
Table 107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
Table 108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
| ※参考情報 神経免疫治療薬は、神経系と免疫系の相互作用に着目した治療薬であり、主に神経疾患や自己免疫疾患の治療に用いられます。近年、神経と免疫の関係性が新たな治療戦略の鍵となっていることが明らかになり、そのために開発されている薬剤の一群を指します。 これらの薬剤の種類には、主に抗体医薬品、免疫調節剤、細胞療法が含まれます。抗体医薬品は、特定のタンパク質や細胞に対して選択的に結合し、免疫応答を修正する役割を果たします。例えば、多発性硬化症の治療に用いられる高親和性のモノクローナル抗体が代表的な例です。これらは免疫系の過剰反応を抑えることに寄与し、神経の損傷を防ぐ効果があります。 免疫調節剤は、免疫系の機能を適切に制御するために用いられる化合物で、体の免疫反応を調整することが目的です。たとえば、アザチオプリンやミコフェノール酸モフェチルなどがあり、これらは自己免疫疾患の治療に広く使われています。これらの薬剤は、白血球の機能を抑制し、炎症を軽減することで神経系に対して保護的な効果をもたらします。 また、細胞療法も神経免疫治療薬の一環として注目されており、特に幹細胞や免疫細胞を用いて神経系疾患を治療する試みが進められています。たとえば、造血幹細胞移植（HCT）は、一部の神経疾患において臨床的に有効とされています。この方法では、体内の疾患を持つ細胞を置き換えることで、正常な細胞の再生を図ります。 神経免疫治療薬の用途は多岐にわたります。多発性硬化症、関節リウマチ、全身性エリテマトーデス（SLE）などの自己免疫疾患の治療が中心であり、最近ではアルツハイマー病やパーキンソン病といった神経変性疾患への応用も模索されています。神経変性疾患においては、炎症を抑制することが疾患の進行を遅らせる可能性があるため、これらの薬剤に期待が寄せられています。 関連技術としては、バイオテクノロジーや遺伝子編集技術があります。特にCRISPR-Cas9技術は、特定の遺伝子を標的とし、その発現を調節することで神経疾患の治療に寄与する可能性があります。また、免疫療法との組み合わせにより、より効果的な治療法が期待されています。 さらに、薬剤の投与方法についても研究が進んでおり、経口薬や注射に加えて、経皮吸収や局所投与といった新しい投与方法が開発されています。これらは患者の体への負担を軽減し、効果を最大化するために重要な要素です。 しかし、神経免疫治療薬には副作用もあるため、安全性や長期的な効果についての研究も進行中です。特に、免疫系を抑制するため感染症のリスクが高まることが懸念されています。そのため、適切な投与量や治療のタイミングについて慎重に検討する必要があります。 これからの研究と開発により、神経免疫治療薬の効果がさらに向上し、新たな治療法が確立されることが期待されています。神経と免疫の相互作用の理解が深まることで、より多様な疾患に対する治療戦略が開発され、患者の生活の質の向上に寄与することにつながるでしょう。神経免疫治療薬の分野は今後ますます重要性を増していくことが予想されます。 |
